Vivex Biomedical Revenue and Competitors

Vinings, GA USA

Location

$14.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vivex Biomedical's estimated annual revenue is currently $44.8M per year.(i)
  • Vivex Biomedical's estimated revenue per employee is $193,750
  • Vivex Biomedical's total funding is $14.2M.

Employee Data

  • Vivex Biomedical has 231 Employees.(i)
  • Vivex Biomedical grew their employee count by -1% last year.

Vivex Biomedical's People

NameTitleEmail/Phone
1
Area VP Sales, Central USReveal Email/Phone
2
VPReveal Email/Phone
3
VP Quality Systems and Regulatory AffairsReveal Email/Phone
4
SVP FinanceReveal Email/Phone
5
VP/GM Ortho & Fusion Therapies BU, VP Strategic AccountsReveal Email/Phone
6
VP Sales, VIVEX BiologicsReveal Email/Phone
7
VP Research and DevelopmentReveal Email/Phone
8
VP SalesReveal Email/Phone
9
VP ReimbursementReveal Email/Phone
10
VP Quality SystemsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$44.8M231-1%$14.2MN/A
#2
$43.6M21719%N/AN/A
Add Company

What Is Vivex Biomedical?

Vivex Biomedical, Inc. develops Biogenic Materials from its Headquarters in Marietta, Georgia. Vivex realizes that creative treatment options and solutions that advance clinical, surgical and therapeutic patient care occur at the interface of diverse technology sectors. In a very short time, some of the brightest minds from the medical and material science industries have been assembled under the guidance of experienced and successful business professionals. The mandate is translation – ideation through clinical implementation.

keywords:N/A

$14.2M

Total Funding

231

Number of Employees

$44.8M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vivex Biomedical News

2021-07-15 - Vivex Biologics, Inc. Launches VIA Mend™ Synthetic Bone Fillers

MIAMI, July 15, 2021 /PRNewswire/ -- Vivex Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced today the launch of VIA Mend™, a line of bone graft substitutes. The innovative line of bone graft substitutes can be ...

2021-05-19 - VIVEX Biologics, Inc. Launches New Family of Allografts, VIAGENEX™

MIAMI, May 19, 2021 /PRNewswire/ -- VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced the launch of VIAGENEX™, a family of amniotic allografts processed to retain the inherent mechanical properties of amnio ...

2017-04-06 - Vivex Biomedical Receives $9m Credit Line

Vivex Biomedical, Inc., an Atlanta, Georgia-based regenerative biologics company, received a $9m line of credit. Heritage Bank of Commerce, the operating bank of Heritage Commerce Corp (NASDAQ:HTBK), provided the financing. The company will use the funds for new product development, to expand ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$55.9M242N/AN/A
#2
$39.9M24210%N/A
#3
$56.6M245-2%N/A
#4
$15M2524%N/A
#5
$67.3M2785%N/A